84 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast PeerView Press

    • Science

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC - Demystifying the Real-World Evidence in Atrial Fibrillation: A Comparative Look at the Direct Oral Anticoagulants for Reducing the Risk of Stroke Among Patients With Nonvalvular Atrial Fibrillation

    Steven B. Deitelzweig, MD, MMM, SFHM, FACP, FACC - Demystifying the Real-World Evidence in Atrial Fibrillation: A Comparative Look at the Direct Oral Anticoagulants for Reducing the Risk of Stroke Among Patients With Nonvalvular Atrial Fibrillation

    Go online to PeerView.com/NNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hospital and vascular medicine discusses how real-world data enhance the data from randomized clinical trials on direct oral anticoagulants (DOACs) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) and offers insight on applying evidence from both real-world studies and randomized clinical trials to improve patient care. Upon completion of this activity, participants will be able to: Identify the role of real-world data and evidence in augmenting the efficacy and safety data that have been collected as part of clinical trials for stroke prevention among patients with NVAF, Compare and contrast evidence collected to date from real-world studies with data reported from clinical trials of DOACs to prevent stroke among patients with NVAF, Apply evidence from real-world studies and clinical trials of DOACs in patients with NVAF

    • 29 min
    John P. Leonard, MD - Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL

    John P. Leonard, MD - Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL

    Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting

    • 1 hr 55 min
    Andre H. Goy, MD - How I Think, How I Treat: BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond—Therapeutic Selection, Sequencing, and Next Steps

    Andre H. Goy, MD - How I Think, How I Treat: BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond—Therapeutic Selection, Sequencing, and Next Steps

    Go online to PeerView.com/FKM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the therapeutic landscape of several lymphoid cancers, including chronic lymphocytic leukemia (CLL), and mantle cell lymphoma (MCL). The present and future management of these diseases will increasingly be defined by the integration of BTK inhibitors—along with other novel therapeutics—into management protocols that have previously been characterized by the use of immunochemotherapy-focused options. Several important practical issues arising from the use of BTK inhibitors, ranging from the initial therapy selection to therapeutic sequencing and use of active combinations, will continue to be a part of patient management for years to come. This PeerView Live “How I Think, How I Treat” on-demand activity, based on a satellite symposium preceding the 61st ASH Annual Meeting and Exposition, exposes learners to the personal insights of several experts in the field and includes in-depth analyses of the cutting-edge science on the present and future role of BTK inhibitors in CLL, MCL, and other lymphoid cancers. Key topics include BTK inhibitor sequencing, selecting patients for treatment, differentiating among first- and second-generation compounds, and safety management. Ultimately, this event provides a “virtual mentorship” experience on the use of BTK inhibitors in several different diseases. Upon completion of this activity, participants should be better able to: Describe updated evidence regarding the use of first- and second-generation BTK inhibitors in the management of B-cell NHL, including agent potency/selectivity, response data, survival outcomes, and activity in BTK inhibitor–intolerant or –resistant disease, Recommend personalized therapy with BTK inhibitors for patients across the spectrum of B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma, among others, Manage unique safety considerations associated with BTK inhibitor therapy in patients with B-cell NHL

    • 1 hr 50 min
    Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

    Joseph K. Han, MD - Driven by Type 2 Inflammation: The Potential of Novel Biologic Therapies in Managing Chronic Rhinosinusitis With Nasal Polyps

    Go online to PeerView.com/QJM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in chronic rhinosinusitis with nasal polyps (CRSwNP) discusses how to diagnose and differentiate this condition from other phenotypes of CRS. Novel agents for the treatment of CRSwNP are also explored, as well as how to incorporate these new therapies into treatment plans. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP) and its relevance to novel therapeutic targets, Apply evidence-based criteria to diagnose and differentiate CRSwNP from other phenotypes of CRS, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRSwNP, Develop individualized treatment plans, including the integration of emerging therapies if/when they become available, for the management of patients with CRSwNP

    • 23 min
    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

    Go online to PeerView.com/EPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses advances in the understanding of the pathogenesis of asthma and novel targeted treatments that have been developed as a result. Strategies for identifying uncontrolled moderate-to-severe asthma patients who would benefit from these agents and clinical data for the currently available and emerging biologic therapies for asthma treatment are also discussed. Upon completion of this activity, participants should be better able to: Describe the economic impact and quality-of-life burden of moderate-to-severe asthma, Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Assess the latest clinical data with regard to efficacy and safety for currently available and emerging biologic therapies for the treatment of severe asthma, Apply treatment for patients with asthma based on symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies

    • 38 min
    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Go online to PeerView.com/YNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView onDemand activity, based on an educational session from the 2019 Scientific Sessions of the American Heart Association in Philadelphia, Pennsylvania, features a panel of cardiology, endocrinology, and primary care experts, who provide their clinical perspectives on assessing patients with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular (CV) disease and other risk factors. These experts discuss recent and emerging data for antihyperglycemic agents (ie, GLP-1 receptor agonists and SGLT2 inhibitors) and how to incorporate this practice-changing information into individualized treatment plans for these high-risk patients. Upon completion of this activity, participants should be better able to: Screen patients with or at high risk of CV disease for T2DM, Assess individual patients with T2DM for risk factors that frequently complicate diabetes management (ie, history of atherosclerotic CV disease, heart failure, chronic kidney disease, hypoglycemia, obesity), Design individualized treatment regimens that consider and incorporate recent and emerging data for antihyperglycemic agents that have been shown to reduce CV risk in patients with T2DM, Collaborate with multidisciplinary colleagues to successfully reduce CV risk in individual patients with T2DM

    • 1 hr 18 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press